Jinghua Pharmaceutical Group Co., Ltd. (SHE:002349)

Market Cap	6.24B -6.4%
Revenue (ttm)	1.45B +0.8%
Net Income	224.79M +3.8%
EPS	0.27 +3.2%
Shares Out	829.67M
PE Ratio	27.41
Forward PE	n/a
Dividend	0.08 (1.06%)
Ex-Dividend Date	Jun 6, 2025

Volume	11,689,154
Average Volume	17,724,870
Open	7.60
Previous Close	7.44
Day's Range	7.43 - 7.60
52-Week Range	6.35 - 8.41
Beta	0.09
RSI	43.82
Earnings Date	Apr 23, 2026

About SHE:002349

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and is based in Nantong, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1957
• Employees: 1,490
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002349

Financial Performance

In 2024, SHE:002349's revenue was 1.40 billion, a decrease of -7.25% compared to the previous year's 1.51 billion. Earnings were 212.65 million, a decrease of -14.15%.